We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00238472
First Posted: October 13, 2005
Last Update Posted: April 27, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
  Purpose
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.

Condition Intervention Phase
Diabetes Mellitus, Type 2 Drug: nateglinide Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Change from baseline in postprandial glomerular filtration rate at 12 weeks

Secondary Outcome Measures:
  • Change from baseline in fasting morning glomerular filtration rate at 12 weeks
  • Change from baseline in postprandial renal plasma flow at 12 weeks
  • Change from baseline in fasting morning renal plasma flow at 12 weeks
  • Change from baseline in adjusted 2-hour postprandial glucose at 12 weeks
  • Change in insulin AUC (0-240 minutes) at 12 weeks

Estimated Enrollment: 24
Study Start Date: May 2003
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Type 2 diabetes diagnosed at least 1 year before inclusion
  • Blood glucose criteria must be met
  • Microalbuminuria criteria must be met

Exclusion Criteria:

  • Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method
  • Blood glucose criteria outside the specified range
  • Microalbuminuria criteria outside the specified range
  • Serious cardiovascular events within the past 6 months
  • Other protocol-defined exclusion criteria may apply
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00238472


Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00238472     History of Changes
Other Study ID Numbers: CDJN608AIT05
First Submitted: October 12, 2005
First Posted: October 13, 2005
Last Update Posted: April 27, 2012
Last Verified: April 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Type 2 diabetes
nateglinide

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Nateglinide
Glyburide
Hypoglycemic Agents
Physiological Effects of Drugs